Congresses and Conferences Committee (C-CC)
C-CC Executive Committee (C-CC-EC)
The Committee on Congresses and Conferences was established in December 2007, and is the continuation of the former Congress and Conference Division (CCD) which was founded in 1996, but with an expanded charter and responsibilities. The C-CC has the major administrative and managerial responsibility within the IFCC for all meetings coordinated by the IFCC.
C-CC Mission statement
The mission of the C-CC is to provide general administration and management of all IFCC meeting activities (congresses, conferences, and symposia) and to review applications for IFCC auspices from non-IFCC conferences requesting such sponsorship.
C-CC Strategy
The C-CC supports and promotes Clinical Laboratory Sciences through congresses, conferences, specialised meetings, and other professional meetings. The C-CC Works closely with the organisers of the various IFCC related conferences to ensure that they achieve organisational and professional excellence.
Projects
-
The C-CC formulates and updates as required the guidelines, procedures and practices for IFCC-designated meetings and also monitors compliance throughout the planning and organizational stages. The C-CC assists the organizing groups in the administration and promotion of conferences, and helps these conferences obtain support, and achieve financial efficiency in the various economical aspects of their meetings.
-
The C-CC reviews all existing meeting guidelines every three years to ensure their continued applicability and will write new guidelines for those meetings not covered by existing procedures.
-
The C-CC maintains a current 5-year listing of congresses and conferences of professional interest to the members of the IFCC, including both IFCC related conferences and those outside the IFCC. This allows members to be aware of these meetings and allows potential conference organisers to plan the dates of their meetings with care.
-
The C-CC designates as official IFCC approved meetings those conferences that conform to the requirements of the IFCC as a professional organisation, in order to promote the field of clinical laboratory sciences and protect the interests of the IFCC. Within the framework of the IFCC designated meetings, the C-CC will promote the IFCC and its functional units and discuss the possibility of integration of IFCC units and members in the programme of the conference.
-
The C-CC assists in expanding the list of IFCC Master Conferences on specific scientific and educational topics and promotes the leadership role of the IFCC in the field of Clinical Laboratory Sciences.
Members of C-CC Executive Committee and terms of appointment
| Name |
Position |
Country |
Term |
Time in Office |
| J. Wesenberg |
Chair |
CA |
1st |
2015 01 - 2017 12 |
| J. Lopez |
Member |
MY |
2nd |
2015 01 - 2017 12 |
| T. Zima |
Member |
CZ |
2nd |
2017 01 - 2019 12 |
| P. Yin |
Corporate Member |
US |
2nd |
2015 01 - 2017 12 |
| M. Blanes Gonzales |
Corresponding Member |
PY |
| R. Erasmus |
Corresponding Member |
ZA |
| A. Hedili |
Corresponding Member |
TN |
| O. Maguire |
Corresponding Member |
IE |
International Congress of Clinical Chemistry and Laboratory Medicine (ICCCLM)
| I |
Amsterdam (NL) |
1954 |
| II |
New York (US) |
1956 |
| III |
Stockholm (SE) |
1957 |
| IV |
Edinburgh (UK) |
1960 |
| V |
Detroit (US) |
1963 |
| VI |
Munich (DE) |
1966 |
| VII |
Geneva/Evian (CH/FR) |
1969 |
| VIII |
Copenhagen (DK) |
1972 |
| IX |
Toronto (CA) |
1975 |
| X |
Mexico City (MX) |
1978 |
| XI |
Vienna (AT) |
1981 |
| XII |
Rio de Janeiro (BR) |
1984 |
| XIII |
The Hague (NL) |
1987 |
| XIV |
San Francisco (US) |
1990 |
| XV |
Melbourne (AU) |
1993 |
| XVI |
London (UK) |
1996 |
| XVII |
Florence (IT) |
1999 |
| XVIII |
Kyoto (JP) |
2002 |
| XIX |
Orlando (US) |
2005 |
| XX |
Fortaleza (BR) |
2008 |
| XXI |
Berlin (DE) |
2011 |
| XXII |
Istanbul (TR) |
2014 |
| XXIII |
Durban (ZA) |
2017 |
| XXIV |
Seoul (KR) |
2020 |
IFCC Regional Congresses
Asian Pacific Federation of Clinical Biochemistry (APFCB)
| III |
Singapore (SG) |
1986 |
| IV |
Hong Kong (HK) |
1988 |
| V |
Kobe (JP) |
1991 |
| VI |
Melbourne (AU) |
1993 |
| VII |
Bangkok (TH) |
1995 |
| VIII |
Kuala Lumpur (MY) |
1998 |
| IX |
New Dehli (IN) |
2001 |
| X |
Perth (AU) |
2004 |
| XI |
Beijing (CN) |
2007 |
| XII |
Seoul (KR) |
2010 |
| XIII |
Bali (ID) |
2013 |
| XIV |
Taiwan (TW) |
2016 |
| XV |
Jaipur (IN) |
2019 |
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM formerly EFCC)
| I |
Munich (DE) |
1974 |
| II |
Prague (CZ) |
1976 |
| III |
Brighton (UK) |
1979 |
| IV |
Vienna (AT) |
1981 |
| V |
Budapest (HU) |
1983 |
| VI |
Jerusalem (IL) |
1985 |
| VII |
Den Hague (NL) |
1987 |
| VIII |
Milan (IT) |
1989 |
| IX |
Crakow (PL) |
1991 |
| X |
Nice (FR) |
1993 |
| XI |
Tampere (FI) |
1995 |
| XII |
Basel (CH) |
1997 |
| XIII |
Florence (IT) |
1999 |
| XIV |
Prague (CZ) |
2001 |
| XV |
Barcelona (ES) |
2003 |
| XVI |
Glasgow (UK) |
2005 |
| XVII |
Amsterdam (NL) |
2007 |
| XVIII |
Innsbruck (AT) |
2009 |
| XIX |
Berlin (DE) (with ICCCLM 2011) |
2011 |
| XX |
Milan (IT) |
2013 |
| XXI |
Paris (FR) |
2015 |
| XXII |
Athens (GR) |
2017 |
| XXIII |
Barcelona (ES) |
2019 |
Latin American Confederation of Clinical Biochemistry (COLABIOCLI)
| S.to Domingo (DO) |
1991 |
| Acapulco (MX) |
1993 |
| Buenos Aires (AR) |
1995 |
| Caracas (VE) |
1997 |
| Puerto Rico (PR) |
1999 |
| Florianopolis (BR) |
2001 |
| San José (CR) |
2003 |
| Asunciòn (PA) |
2006 |
| Panama (PAN) |
2007 |
| Santiago (CL) |
2010 |
| Punta Cana (DO) |
2011 |
| Lima (PE) |
2013 |
| Quito (EC) |
2015 |
| Punta del Este (UY) |
2017 |
Arab Federation of Clinical Biochemistry (AFCB)
| Cairo (EG) |
1974 |
| Faihaa (SY) |
1976 |
| Cairo (EG) |
1980 |
| Cairo (EG) |
1983 |
| Cairo (EG) |
1986 |
| Tunis (TN) |
1991 |
| Faihaa (SY) |
1994 |
| Amman (JO) |
1997 |
| Rabat (MA) |
2000 |
| Monastir (TU) |
2004 |
| Damascus (SY) |
2006 |
| Beirut (LB) |
2009 |
| Marrakesh (MA) |
2012 |
| Karthoum (SD) |
2015 |
African Federation of Clinical Chemistry (AFCC)
| Ibadan (NG) |
2009 |
| Nairobi (KE) |
2011 |
| Harare (ZW) |
2015 |
IFCC Specialized Conferences
IFCC-Roche Diagnostics Bergmeyer Conferences
Goals and Objectives
- The Bergmeyer Conferences founded in 1987 are a collaborative effort of IFCC and Roche Diagnostics focused on standardisation issues.
- The objectives of these Conferences are:
- Improving the Comparability and Compatibility of Laboratory Assay results in life sciences;
- Improving the Clinical Value of Laboratory Data;
- Discussion of Standardisation Issues and suggesting solutions in order to achieve the first two objectives;
- Master Discussion of Experts and a Brain Storming Forum for projects to be executed by Scientific Division's Committees or Working Groups.
- Each Conference is devoted to a rapid developing new area relevant for laboratory science and clinical medicine. The scope of a Conference is to be organised in that manner that besides comprehensive review also future trends, analytical pitfalls and the rationale, clinical use of the diagnostic procedures have to be considered.
- These Conferences are Master Discussions of experts in the respective topic of a Conference. Participation is only possible on invitation.
- The governing body of these Conferences is the Steering Committee consisting of IFCC (3), the editor of the proceedings (1) and Roche Diagnostics (1) representatives.
- Conferences are held in Eibsee, Germany.
- Lectures and contributions presented at the Conferences are published in the Conference proceedings.
Terms of Reference
- Organisation of Bergmeyer Conferences: selection of date and topic; responsibility for the scientific content and selection of speakers;appointment of an ad hoc Working Group (occasionally) for the preparation of draft documents to be circulated prior to the respective Conference to the participants; review of the organisational and financial commitments.
- Review of documents produced in conjunction with each Conference;
- Submission of documents to the Scientific Division for final approval;
- Publication of proceedings - Appointment of editors;
- The Proceedings are published in the Scandinavian Journal;
- Collaboration with Roche Diagnostics and the local organising group
- Report to Scientific Division, information to the Congresses and Conferences Committee;
- The Membership to be nominated by SD and approved by EB. The terms of the IFCC members are usually 3 years; re-appointments are possible.
| Steering Committee |
Position |
Country |
Time in Office |
| I. Young |
IFCC Steering Committee Chair and IFCC SD-Chair |
UK |
2011 - 2016 |
| J. Passarelli |
Roche Diagnostics |
US |
2011 - 2017 |
| A. Kallner |
Editor of Proceedings |
SE |
1988 - on going |
| L. Lai |
IFCC EMD-Chair |
MY |
2015 - 2017 |
| J. Wesenberg |
IFCC - C-CC Chair |
CA |
2015 - 2017 |
Recent Conferences:
| VII |
1999 |
Biochemical markers for myocardial damage |
| VIII |
2001 |
Biochemical markers of autoimmune disease |
| IX |
2003 |
Nucleic acid markers for bacterial and viral infections in intensive care |
| X |
2005 |
Diabetes and cardiovascular disease |
| XI |
2008 |
Markers of kidney disease |
| XII |
2010 |
Novel biomarkers: from discovery to clinical application |
| XIII |
2012 |
Vitamin D in health and disease |
| XIV |
2014 |
Women's Health |
| XV |
2016 |
Biomarkers in the Diagnosis and Monitoring of Cancer |
Congress Guidelines and Other Documents
The following documents have been prepared by the C-CC.
- Auspices of the IFCC - Guidelines and Procedures
- Guidelines for International Congresses of Clinical Chemistry and Laboratory Medicine (ICCCLM)
- Guidelines for EFCC European Congresses of Clinical Chemistry and Laboratory Medicine (EuroMedLab)
IFCC General Conference
Aim
The aim of the IFCC General Conference is to convene all the IFCC functional units at one time and location, in order to discuss present activities and projects, and to plan and decide on future actions of the organization.
Responsibilities
- The Committee on Congresses and Conferences (C-CC) of the IFCC bears overall responsibility for the organization of the General Conference.
- The IFCC Secretary is responsible for the Conference agenda.
- The IFCC Executive Board is responsible for detailed programme content
- The IFCC Office will carry out the administrative activities in preparing for the Conference in collaboration with the C-CC and a local organizing committee from the national society of the country where the meeting is being held.
Time and Venue
- A General Conference is held once during the triennial term of the Executive Board (EB) of IFCC, usually during the second year. The EB decides on the time of the year at which to hold this Conference.
- The EB will decide on the venue for the IFCC General Conference following a recommendation from the C-CC.
- The duration of the General Conference is 2 days, and is preceded by 2 days of an EB meeting and meetings of the Divisions and Committees. This period is required to enable all the IFCC functional units to meet individually and collectively.
Scope
- Prior to the General Conference all IFCC functional units carry out their own meetings, meet with their immediate and/or Divisional supervisors, and report on the progress of their projects and on project proposals. The Division Executive Committees then meet with the EB to present the status of their Division, and to obtain consent for future and/or continuing activities.
- Representatives from Full Members and Corporate Members join IFCC functional units for the General Conference proper.
Conferences:
| I |
Rungestedgaard (DK) |
1981 |
| II |
Rungestedgaard (DK) |
1984 |
| III |
Monza (IT) |
1988 |
| IV |
Pont-à-Mousson (FR) |
1992 |
| V |
Leipzig (DE) |
1995 |
| VI |
Sevilla (ES) |
1998 |
| VII |
Dubrovnik (HR) |
2001 |
| VIII |
Sousse (TN) |
2004 |
| IX |
Antalya (TR) |
2008 |
| X |
Corfu (GR) |
2010 |
| XI |
Kuala Lumpur (MY) |
2012 |
| XII |
Madrid (ES) |
2016 |
Committee members' contact details
Prof. James WESENBERG
Clinical Laboratory
Red Deer Regional Hospital Center
3942 50A Avenue
Red Deer, Alberta, T4N 4E7, Canada
e-mail: james.wesenberg@albertahealthservices.ca
Mr. Joseph LOPEZ
Dept. of Biomedical Sciences
MAHSA University College
50490 Kuala Lumpur, Malaysia
e-mail: jblopez@streamyx.com
Prof. Tomas ZIMA
Institute of Clinical Biochemistry and Laboratory Medicine
1st Medical Faculty and General Teaching Hospital
Charles University,
U Nemocnice 2,
CZ-12108 Prague2, Czech Republic
e-mail: zimatom@cesnet.cz
Dr. Peng YIN
Director R&D Abbott
Abbott 476 Li Bing Road
Shanghai, China 201203
e-mail: peng.yin@abbott.com
Corresponding Members:
Prof. Montserrat BLANES GONZALES
Paraguayan Social Security Institute
Av.da Sacramento y Dr Peña
Asuncion, Paraguay
e-mail: mblanes@ips.gov.py
Prof. Rajv ERASMUS
Dept of Chemical Pathology
PO Box 19113
Tygerberg, 7505, South Africa
e-mail: rte@sun.ac.za
Prof. Abderrazek HEDILI
10 Rue Aboul Kacem Chebbi
1008 Montfleury
Ms. Orla MAGUIRE
Clinical Biochemistry Department,
St Vincent's University Hospital
Elm Park
Dublin 4, Ireland
e-mail: o_maguire@hotmail.com